NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Alloy Therapeutics

Alloy Therapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://alloytx.com/

Last Round

Series E

Apr 15, 2026

Est. Valuation

$1B

Total Funding Raised

$185.75M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Alloy Therapeutics is a biotechnology ecosystem company that provides AI-powered platforms, scientific expertise, and integrated services to support drug discovery and development across multiple therapeutic modalities.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS, Data as a Service

AI Layer

Application

Keywords

antibody discoverydrug discovery platformbiotech infrastructurediscovery-as-a-servicetransgenic animal modelsAI-driven drug discoveryprotein engineeringcontract research organizationCROgenetic medicinein silico drug designbiotech R&Dantibody therapeuticsbiotech platformpharma outsourcing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alloy Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Alloy Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Alloy Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series EApr 15, 2026
Series DOct 3, 2022
Series CApr 2, 2021
Series BMay 1, 2020

Key People

Founding team and executive leadership

Kelsey Cardenas

Director, Office Of The CEO

Executive Team

Logan Snyder

Board Member, Office Of The CEO

Executive Team

Jeff Swenson

Acting Chief Financial Officer

Executive Team

Alloy Therapeutics Investors

Notable investors and investment history

Alloy Therapeutics investors
InvestorRounds
Echo Investment CapitalSeries E
Thiel CapitalSeries E, Series D
GaingelsSeries C, Series E
Pathfinder Venture CapitalSeries C, Series E, Series D
Presight CapitalSeries E, Series D, Series C
JIC Venture Growth InvestmentsSeries E
Mubadala CapitalSeries E, Series C, Series D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    100% of revenue reinvested into innovation and access.

  • Apr 15, 2026

    $40M round closed at $1B valuation.

Alloy Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alloy Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alloy Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range144
Year Founded2017
Last FundingApr 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.